492 related articles for article (PubMed ID: 18025070)
1. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Niwa H; Wentzel AL; Li M; Gooding WE; Lui VW; Grandis JR
Clin Cancer Res; 2003 Oct; 9(13):5028-35. PubMed ID: 14581378
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
[TBL] [Abstract][Full Text] [Related]
4. Antisense treatment of IGF-IR enhances chemosensitivity in squamous cell carcinomas of the head and neck.
Liu S; Jin F; Dai W; Yu Y
Eur J Cancer; 2010 Jun; 46(9):1744-51. PubMed ID: 20451373
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ
Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.
Li M; Ye C; Feng C; Riedel F; Liu X; Zeng Q; Grandis JR
Clin Cancer Res; 2002 Nov; 8(11):3570-8. PubMed ID: 12429648
[TBL] [Abstract][Full Text] [Related]
7. An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma.
Yoo GH; Subramanian G; Boinpally RR; Iskander A; Shehadeh N; Oliver J; Ezzat W; Piechocki MP; Ensley JF; Lin HS; Shibuya TY; Polin L; Parchment RE
Arch Otolaryngol Head Neck Surg; 2005 May; 131(5):418-29. PubMed ID: 15897421
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model.
Yoo GH; Subramanian G; Ezzat WH; Tulunay OE; Tran VR; Lonardo F; Ensley JF; Kim H; Won J; Stevens T; Zumstein LA; Lin HS
Am J Otolaryngol; 2010; 31(2):78-83. PubMed ID: 20015717
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
Saigal B; Glisson BS; Johnson FM
Anticancer Drugs; 2008 Jun; 19(5):465-75. PubMed ID: 18418213
[TBL] [Abstract][Full Text] [Related]
10. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
11. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Zhang X; Chen ZG; Choe MS; Lin Y; Sun SY; Wieand HS; Shin HJ; Chen A; Khuri FR; Shin DM
Clin Cancer Res; 2005 Sep; 11(17):6261-9. PubMed ID: 16144930
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
14. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo.
Endo S; Zeng Q; Burke NA; He Y; Melhem MF; Watkins SF; Lango MN; Drenning SD; Huang L; Rubin Grandis J
Gene Ther; 2000 Nov; 7(22):1906-14. PubMed ID: 11127578
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Choe MS; Chen Z; Klass CM; Zhang X; Shin DM
Clin Cancer Res; 2007 May; 13(10):3015-23. PubMed ID: 17505004
[TBL] [Abstract][Full Text] [Related]
16. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
18. EGFR antisense treatment of human HNSCC cell lines down-regulates VEGF expression and endothelial cell migration.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2002 Jul; 21(1):11-6. PubMed ID: 12063543
[TBL] [Abstract][Full Text] [Related]
19. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]